1. To characterize the demographics and clinical course of the patient population diagnosed as having WHO group I pulmonary arterial hypertension and WHO group IV pulmonary hypertension due to chronic thromboembolic pulmonary hypertension 2. To describe real-world outcome of Chinese patients with WHO group I pulmonary arterial hypertension and WHO group IV pulmonary hypertension due to chronic thromboembolic pulmonary hypertension 3. To evaluate differences in patient outcomes according to classification subgroup 4. To identify clinical predictors of long-term survival 5. To assess the relationship between targeted therapies for pulmonary arterial hypertension and patient outcomes
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Survival
Timeframe: 5 years